Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research (Excluding Clinical Trials)

Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis

Molly Kozminsky, Hyeun Joong Yoon, Nallasivam Palanisamy, Kathleen Cooney, Maha Hussain, Ajjai Alva, Todd Morgan and Sunitha Nagrath
Molly Kozminsky
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hyeun Joong Yoon
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nallasivam Palanisamy
Henry Ford Health System, MI.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen Cooney
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maha Hussain
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ajjai Alva
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Morgan
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunitha Nagrath
University of Michigan, Ann Arbor, MI;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-1585 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

One in seven men in the United States will be diagnosed with prostate cancer in his life time, in part because of the prevalence of screening for serum levels of prostate specific antigen (PSA). However, this has led to the overtreatment of the disease, leading to recommendations against frequent PSA testing and establishing the need for a more informative biomarker in prostate cancer. Circulating tumor cells (CTCs) are rare cells present in the blood stream of cancer patients at the low frequency on the order of one CTC in one billion normal blood cells. The graphene oxide chip (GO Chip) is a microfluidic CTC capture device with increased sensitivity and purity due to its use of the nanomaterial graphene oxide to present a capture antibody against the epithelial cellular adhesion molecule (EpCAM). In this study, whole blood was collected from 50 prostate cancer patients, including those with metastatic, localized, castrate resistant, and castrate sensitive disease, and analyzed using the GO Chip. Captured cells were stained for cytokeratin, CD45, and DAPI, with nucleated cytokeratin positive cells being denoted as CTCs. CTCs were detected in 47 out of 50 patients, and an average of 5.94 CTCs/mL was recovered from each sample. Correlation of CTCs with surrogate endpoints could improve the utility of CTCs as a liquid biopsy, potentially advancing their application in translational research.

Citation Format: Molly Kozminsky, Hyeun Joong Yoon, Nallasivam Palanisamy, Kathleen Cooney, Maha Hussain, Ajjai Alva, Todd Morgan, Sunitha Nagrath. Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1585. doi:10.1158/1538-7445.AM2015-1585

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis
Molly Kozminsky, Hyeun Joong Yoon, Nallasivam Palanisamy, Kathleen Cooney, Maha Hussain, Ajjai Alva, Todd Morgan and Sunitha Nagrath
Cancer Res August 1 2015 (75) (15 Supplement) 1585; DOI: 10.1158/1538-7445.AM2015-1585

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 1585: Application of a graphene oxide based microfluidic device (GO Chip) to prostate cancer circulating tumor cell capture and analysis
Molly Kozminsky, Hyeun Joong Yoon, Nallasivam Palanisamy, Kathleen Cooney, Maha Hussain, Ajjai Alva, Todd Morgan and Sunitha Nagrath
Cancer Res August 1 2015 (75) (15 Supplement) 1585; DOI: 10.1158/1538-7445.AM2015-1585
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research (Excluding Clinical Trials)

  • Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas
  • Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
  • Abstract LB-251: Development of a circulating microRNA risk signature predictive of breast cancer diagnosis among high-risk women
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas
  • Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)
  • Abstract LB-251: Development of a circulating microRNA risk signature predictive of breast cancer diagnosis among high-risk women
Show more 3

Poster Presentations - Circulating Tumor Cells

  • Abstract 1591: Comprehensive molecular profiling of circulating tumor cells from metastatic breast cancer patients
  • Abstract 1601: Clinical performance of the AccuCyte® - CyteFinder® System, a dual-technology platform for comprehensive collection and high resolution imaging of circulating tumor cells
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement